Anaconda Biomed
Funnel-catheter thrombectomy devices for acute ischemic stroke
Anaconda Biomed is a Barcelona-based medical technology company, also operating from Marin, California, that develops thrombectomy catheters for acute ischemic stroke around its proprietary Funnel Catheter platform. The device combines large-bore aspiration with the flow-arrest and flow-reversal benefits of balloon guide catheters to capture clots and microemboli. The ANA5 Funnel Catheter is CE-marked, while the ANA Funnel Catheter is investigational in the US and is being evaluated in the 327-subject ATHENA pivotal IDE trial. On September 23, 2026 the company closed a $56 million financing led by Omega Funds, with new investor FOCO and existing backers Asabys, Ysios Capital and CDTI. It runs its own production facility on the edge of Barcelona. Not to be confused with Anaconda, Inc., the Python software company.
Healthcare
📍 Barcelona, Spain
Founded 2015
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Anaconda Biomed going public?
No. Anaconda Biomed is private and has not filed to go public. There is no S-1 on file.
What is Anaconda Biomed's valuation in 2026?
No confirmed valuation is on record for Anaconda Biomed. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Anaconda Biomed filed an S-1?
No public S-1 is on file for Anaconda Biomed.
Who are Anaconda Biomed's investors?
Anaconda Biomed's investors include Omega Funds, FOCO (COFIDES), Asabys Partners, Ysios Capital, CDTI (Innvierte), Innogest and 2 more.
Is Anaconda Biomed publicly traded — can you buy Anaconda Biomed stock?
No. Anaconda Biomed is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Anaconda Biomed on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Last Round
Growth financing (unlabeled) — $56M (Sep 2026) · Lead: Omega Funds
Fundraising Status
Growth financing (unlabeled) · $56M · this month
private3 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Growth financing (unlabeled) | $56M | Sep 2026 | Omega Funds | — |
| Venture debt (EIB) | — | Oct 2021 | European Investment Bank | — |
| Series B | — | Dec 2019 | Asabys Partners | — |
Talent Signal
Hiring data for Anaconda Biomed has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
Investors
Omega Funds · FOCO (COFIDES) · Asabys Partners · Ysios Capital · CDTI (Innvierte) · Innogest · Sabadell Venture Capital · European Investment Bank
Products
- ANA Funnel Catheter (ANA5, ANA6, ANA8)
- Conda stent retriever
Competitors
Penumbra (Boston Scientific) · Imperative Care
MedTechStrokeNeurovascularMedical DevicesSpainClinical Stage
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.